Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566156 · ClinicalTrials.gov registry record · Phase 3
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A Phase 3 study, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT07566156 is a Phase 3 study that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 390 participants.
The verdict
NCT07566156, a Phase 3 study, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Interventions
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Enfortumab vedotin
- RADIATION Hypofractionated Radiotherapy
- RADIATION Conventional Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2032-02-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566156
The ClinicalTrials.gov registry entry for NCT07566156 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT07566156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566156 about?
NCT07566156 is a clinical study titled "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)". This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this canc...
What is the current status of trial NCT07566156?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2026-05-11. Estimated completion is 2032-02-29.
What interventions are being tested in trial NCT07566156?
The interventions under investigation include: Cisplatin (DRUG), Fluorouracil (DRUG), Enfortumab vedotin (DRUG), Hypofractionated Radiotherapy (RADIATION), Conventional Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT07566156?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.